October 21, 2016
Premaitha Health issues 940,000 options
Premaitha Health has issued 940,000 options over ordinary shares under the Company’s unapproved share option scheme to two employees.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 20, 2016
Esperite starts developing inflammatory bowel disease therapies; Starts with Crohn`s disease
Esperite`s business unit The Cell Factory in collaboration with Women`s and Children`s Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).
October 20, 2016
Transgene announces €48 M rights issue, reports €1,1M operating revenue decrease
Transgene, a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the launch and terms of a share capital increase with shareholders’ preferential subscription rights for a total gross amount of circa €48 million, issue premium included (the “Rights Issue”).
October 20, 2016
Genomic Vision presents the initial results of the pilot study undertaken with quest diagnostics in spinal muscular atrophy
Genomic Vision, DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, has presented, at the Annual Meeting of the American Society of Human Genetics, the initial results of the pilot study undertaken with Quest Diagnostics that aims to identify a biomarker to improve genetic counseling for Spinal Muscular Atrophy (SMA) in the African-American population.
October 20, 2016
NCI picks ATCC to distribute tancer models for supporting human cancer models initiative
The National Cancer Institute (NCI) awarded ATCC, a global player in biological materials management and standards, a contract to distribute a new generation of …
October 20, 2016
Roche sees sales growth, praises Tecentriq performance
The Swiss-based pharmaceutical major Roche has see a sales growth for the first three quarters of 2016, praising good performance of Tecentriq, it’s anti PD-L1 cancer immunotherapy that was approved for non-small cell lung cancerby the US FDA in May this year.
October 20, 2016
FDA approves Lilly’s Lartruv for soft tissue sarcoma treatment
Eli Lilly and Company announced that FDA has granted approval of LARTRUV (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
October 20, 2016
Sun Pharma and ICGEB collaboration for development of a dengue vaccine
International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma have announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans.
October 20, 2016
Quantum Pharma plans raising £15M by placing shares
The company on Thursday said the Placing Shares are being offered by an accelerated bookbuild. Zeus Capital and N+1 Singer will be acting as joint bookrunners in connection with the Bookbuild, Quantum Pharma has said.
October 19, 2016
Pfizer’s Inflectra (Chron’s disease) soon available in US
Pfizer will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE 1 (infliximab) to wholesalers in the United States (U.S.) in late November 2016.